1-(3-溴-5-甲氧基苯基)乙酮 | 1073642-71-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3-溴-5-甲氧基苯基)乙酮
• 英文名称: 1-(3-bromo-5-methoxyphenyl)ethanone
• CAS: 1073642-71-3
• 化学式: C₉H₉BrO₂
• 分子量: 229.073
• InChiKey: NFBOXKSRASBKQU-UHFFFAOYSA-N

物化性质

• 熔点：
  36-38°C
• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2914700090

反应信息

• 作为反应物：
  描述：

  1-(3-溴-5-甲氧基苯基)乙酮 在 bis-triphenylphosphine-palladium(II) chloride 、 mercury(II) diacetate 、 potassium carbonate 、 caesium carbonate 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 15.08h， 生成 6-(3-methoxy-5-prop-2-ynylphenyl)-2,3-dihydro-benzo[1,4]dioxine
  参考文献：
  名称：

  两种念珠菌二氢叶酸还原酶活性位点的结构分析揭示了物种间共有的配体诱导的构象变化

  摘要：

  一种针对病原体白色念珠菌和光滑念珠菌的新策略侧重于开发对二氢叶酸还原酶有效的强效选择性抗叶酸剂。晶体结构分析表明，活性位点 (Thr 58-Phe 66) 上的一个基本环不同于人类酶中的类似残基，这可能为实现选择性提供了一种机制。为了探索这个回路的作用，我们采用了化学合成、晶体结构测定和分子动力学模拟。这些分析的结果表明，环残基经历了配体诱导的构象变化，这在真菌和人类物种中是相似的。

  DOI：

  10.1016/j.bmcl.2013.01.008
• 作为产物：
  描述：

  N,N-二甲基乙酰胺 、 3,5-二溴苯甲醚 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.33h， 以71%的产率得到1-(3-溴-5-甲氧基苯基)乙酮
  参考文献：
  名称：

  Structure-Based Approach to the Development of Potent and Selective Inhibitors of Dihydrofolate Reductase from Cryptosporidium

  摘要：

  Cryptosporidiosis is an emerging infectious disease that can be life-threatening in ail immune-compromised individual and causes gastrointestinal distress lasting up to 2 weeks in an immune-competent individual. There are few therapeutics available for effectively treating this disease. We have been exploring dihydrofolate reductase (DHFR) as a potential target in Cryptosporidium. On the basis of the structure of the DHFR enzyme from C. hominis, we have developed a novel scaffold that led to the discovery of potent (38 nM) and efficient inhibitors of this enzyme. Recently, we have advanced these inhibitors to the next stage of development. Using the Structures of both the protozoal and human enzymes. we have developed inhibitors with nanomolar potency (1.1 nM) against the pathogenic enzyme and high levels (1273-fold) of selectivity over the human enzyme.

  DOI：

  10.1021/jm8009124

文献信息

• TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
  申请人：HEINELT Uwe

  公开号：US20110034452A1

  公开（公告）日：2011-02-10

  The invention relates to novel compounds of formula I where X, A − , Q1, Q2 Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.

  这项发明涉及公式I的新化合物， 其中X，A − ，Q1，Q2，Q3，R2，R3，R4，R5，R6，R7，R8和R9分别如下定义。公式I的化合物具有抗血栓活性，特别是抑制蛋白酶活化受体1（PAR1）。该发明还涉及制备公式I化合物的方法以及将其用作药物的用途。
• Inhibitors of Dihydrofolate Reductase With Antibacterial Antiprotozoal, Antifungal and Anticancer Properties
  申请人：Anderson Amy C.

  公开号：US20090105287A1

  公开（公告）日：2009-04-23

  The compositions and methods described herein discloses the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus , fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii . These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.

  本文描述的组合物和方法揭示了设计、合成和测试作为DHFR抑制剂的化合物。这些抑制剂的基本骨架包括一个2,4-二氨基嘧啶环，带有一个丙炔基连接到另一个取代芳基、双环或杂环芳基环。这些DHFR抑制剂对许多不同的病原体具有强大的选择性作用，包括来自细菌如炭疽芽胞杆菌和耐甲氧西林金黄色葡萄球菌、真菌如白色假丝酵母、白念珠菌和新生隐球菌，以及原虫如人类隐孢子虫和弓形虫的DHFR酶。这些化合物和其他类似化合物也对哺乳动物酶具有强大的作用，可能有助于作为抗癌治疗药物。
• TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
  申请人：HEINELT Uwe

  公开号：US20110034451A1

  公开（公告）日：2011-02-10

  The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.

  该发明涉及公式I的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、Q1、Q2和Q3分别如下定义。公式I的化合物具有抗血栓活性，特别是抑制蛋白酶活化受体1（PAR1）。该发明还涉及制备公式I化合物的方法以及将其用作药物的用途。
• CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF
  申请人：AiCuris GmbH & Co. KG

  公开号：US20150105388A1

  公开（公告）日：2015-04-16

  This invention relates to new carboxamide-substituted heteroaryl-pyrazoles, method for their production, their use for the treatment and/or prophylaxis of diseases, as well as their use for the production of pharmaceutical agents for the treatment and/or prophylaxis of diseases, in particular retroviral diseases, in humans and/or animals.

  本发明涉及新的羧酰胺取代的杂环基吡唑啉，其生产方法，它们用于治疗和/或预防疾病，以及它们用于生产用于治疗和/或预防疾病的药物制剂，特别是用于治疗和/或预防人类和/或动物的逆转录病毒性疾病。
• Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments
  申请人：Sanofi-Aventis

  公开号：US08076336B2

  公开（公告）日：2011-12-13

  The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.

  本发明涉及公式I的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、Q1、Q2和Q3分别如下定义。公式I的化合物具有抗血栓活性，特别是抑制蛋白酶活化受体1（PAR1）。本发明还涉及制备公式I化合物的方法以及将其用作药物的用途。